📣 Happy to share a preprint of our latest manuscript, available now in #bioRxiv. In this work we use #DNAbarcoding, #lineagetracing and #singlecell technologies to interrogate #plasticity and #cancerevolution in #neuroblastoma. We show that… 👇🧵 https://t.co/OBA3Q6BAKW

I am moving to bsky: @alejandrapcelab.bsky.social

JOB ALERT!🚨 The @MansfeldLab is #hiring a Postdoc to characterise how protein oxidation regulates cell cycle proteins involved in #DNAReplication, #DNADamage, or #Ubiquitylation. Don’t miss out, apply!

It was a collaborative effort led by @PaedCancerEvol, @OMRueda, @JeanEAbraham722 & @CarlosC24501217.

@CaldasLab @CRUK_CI @MRC_BSU @Cambridge_Uni @ICR_London Big shout out to AMAZING Abby, a force of nature that drove this research forward despite many drawbacks. You are a super star! HUGE CONGRATULATIONS @Abigail_Shea1.

❤️ Thank you to the patients who donated to this research, our research institutes and funders. This research was conducted in @CaldasLab and @PaedCancerEvol at @CRUK_CI, @MRC_BSU, @Cambridge_Uni and @ICR_London.

🧵 (3/3) We then used the platform to study cancer evolution and showed: 💡permanent non-genetic phenotypic changes in response to Olaparib. 💡tumours undergo treatment-specific functional changes. Importantly, some of these changes affected responses to next-line treatments.

🧵 (2/3) We next tested PDX responses to alternative clinical trial arms and other relevant treatments. 💡These data suggest PDXs could be used as anticipatory tools. However, we also highlighted important considerations when using PDXs in this way.

We developed a co-clinical trial platform for treatment-naïve triple-negative breast cancer. In vivo PDXs and ex vivo PDTCs were treated in parallel with patients. 💡 PDXs accurately mirrored clinical drug responses of their matched patient.

🆕 Breast cancer PDX paper out in Cancer Research ‼️ Breast cancer PDXs can predict patient drug responses, and model phenotypic and functional cancer evolution. Full text available: https://t.co/nUeiuLHvhn 🧵Key findings: 👇 #cancerresearch #breastcancer #xenografts

I sincerely appreciate the invitation and the warm welcome. It was an honour to learn about the remarkable research being conducted at your institute. Thank you for sharing such valuable insights.

📆 Only one week left to apply to our exciting postdoc position, closing the 24th! Please RT and share with your network:

Thank you, too, to the amazing @Cecilia Roux who was instrumental in developing this research idea (and who will also be instrumental in delivering its success).

THANK YOU #Littleprincesses. I am honoured to receive a New Ideas Grant from @LPTrustUK. I am grateful for their support and excited to contribute to advancements in paediatric cancer treatment. #ChildhoodCancer #ResearchForACure #ICR https://t.co/0b7pDepcKT

ANNUAL REPORT 2022/2023: Pleased to share a summary of our record-breaking year. To find out more access the link. https://t.co/TGgYwYnfSk #rhabdomyosarcoma #TogetherWeAreStronger #thearcs

Nature research paper: Symbolic recording of signalling and cis-regulatory element activity to DNA

We’ve had a great afternoon of short talks at the #CBTCESummerSchool24. Thanks to Dr Alejandra Bruna @PaedCancerEvol @ICR_London, Prof. Kevin Brindle @CRUK_CI, Dr @mad_lancaster @Cambridge_Uni and Dr Raj Jena @ml4cancer @CUH_NHS for presenting their work. @CRUKCBTCE

https://t.co/eCDtmDzxJ4

🔗 Apply now: https://t.co/dnp2PbtdQ2 #PhD #ClinicalResearch #CancerResearch #HealthcareChoices

🚀 Exciting Opportunity! 🚀 We're seeking passionate clinicians to join our Clinical PhD Fellowships at @PaedCancerEvol at the @ICR_London . Advance your career in cancer research, gain expertise, and make a significant impact. 🎓🔬

Delighted to host an RMS strategy setting day. The purpose was to commence the process of defining UK RMS research priorities over the next ten years. Inspired by a collection of patient advocates, clinicians, scientists & professionals from other disease types. #futureresearch